In our study, skin AEs occurred in 64.5% of patients; the incidences of rash, pruritus, and vitiligo are similar to those after anti–PD-1 monotherapy (10–20%) (Weber et al., 2017b; Eggermont et al., 2018). The gene discussed is RPL17; the disease is vitiligo.